Skip to main content

Antibody Technology Interest Network


The Antibody Technology Research Group (ARG) transitioned in 2018 to become the Antibody Technology Interest Network.

The Antibody Technology Interest Network is dedicated to: 

  • Sharing its collective knowledge about generating, producing, purifying, fragmenting and conjugating antibodies amongst its members and within the larger scientific community
  • Providing a mechanism by which protocols, organizational structures and fiscal approaches can be collected, shared and compared
  • Advancing and evaluating the technology within the antibody field (i.e. rabbit monoclonal antibodies, phage display technology)

Current Membership

David Blum (Chair) - University of Georgia
Sabin Antony - The Jackson Laboratory
Dennis Bagarozzi - Centers for Disease Control and Prevention
Shadi Bootorabi - University of Florida
Robert H Carnahan - Vanderbilt University Medical Center
Philip Gao - University of Kansas
Angel Sampson - University of Florida
Alan Sawyer - The Jackson Laboratory
Tracy Triplett - Vanderbilt University
Frances Weis-Garcia - Memorial Sloan Kettering Cancer Center
Allis Chien
(EB Liaison) - Stanford University


1)Comparison of the impact of antibody labeling on performance. Three distinct antibody-labeling approaches are being compared to determine their impact on the functionality of antibodies previously determined to be “difficult to label”.
2)Immunization Strategy Comparison. Many factors impact the ultimate immune response in experimental host systems. To better develop more effective immunization strategies, we have identified a several different approaches to developing a robust humoral immune response and are directly comparing them.


1)Antibody Protocols Resource. Love them or Hate them … Harnessing the power of antibodies is not always easy ... Antibodies are extremely powerful reagents in a scientist’s toolbox. To make it easier to create novel antibodies for and use existing antibodies in your unique experiments, the Antibody Technology Research Group is compiling a dynamic intellectual repository focused on antibodies technologies enabling all of us to address our own antibody challenges by continuously learning from each other. We invite you to spend 5 to 15 minutes sharing your knowledge from which the initial installment will be created. In return, you and your institutions will be cited for each contribution in the antibody repository and you will have access to it’s complied knowledge before it goes public. Submission topics include, but are by no means limited to: • Generating novel antibodies (immunization strategies, fusion protocols, screening strategies) • Producing and purifying antibodies • Labeling antibodies • Using antibodies (i.e. Flow Cytometry, Microscopy, ChIp-Seq, In vivo applications). To learn more, please review the attachment below which contains the complete announcement, people to contact and a sample PEG based somatic cell fusion protocol.
    - Love them or Hate them … 
2)The Perfect Antibody Initiative. Antibodies are powerful tools used extensively in biomedical research. Unfortunately, they are not all created equal when it comes to the techniques in which they work, their specificity, and sad to say their reproducibility across batches, polyclonal antibodies being particularly affected by the latter. Thus, finding an antibody that works in an experiment is often a very time consuming and costly process. Following up on our 2012 roundtable, we are continuing a dialogue in various formats as to the challenge of finding the “perfect” antibody and what a solution needs to contain. Efforts are ongoing to: 1) To create a series of articles around related to the Perfect Antibody Initiative 2) Spread awareness of the ABRF/ABRF, the current efforts and the Perfect Antibody Initiative 3) Publish iteration of blog series into a comprehensive article for ABRF journal


Virtual Lab Meetings
Perfect Antibody Blog Posts

    - On OneDegreeBio website 
    - On LinkedIn 

Membership History

Member NameOrganizationDetails
Brian J. Agnew Member: 07/12 - 03/13
Sabin AntonyThe Jackson LaboratoryMember: 09/18 -
Dr. Jessica BackKarmanos Cancer Institute Member: 07/12 - 03/13
Dennis BagarozziCenters for Disease Control and PreventionMember:
Dr. David BlumUniversity of Georgia Member: 06/12 - 04/13
Co-Chair: 04/13 - 04/14
Chair: 04/14 -
Kathleen M. Brundage West Virginia UniversityMember: - 04/18
Dr. Robert H. CarnahanVanderbilt University Medical Center Member: 03/13 -
Co-chair: 04/10 - 03/13
Allis ChienStanford UniversityEB Liaison: 02/16 - 
Dan L. CrimminsWashington University School of MedicineMember: - 08/18
Philip GaoUniversity of KansasMember:
Ms. Linda G. GreenUniversity of Florida Member: 04/11 - 03/13
Mr. Gregory R. HalversonNew York Blood Center Member: 08/10 - 03/13
Dr. John E. HarlanAbbott Laboratories Member: 07/10 - 03/12
Ad hoc: 04/12 - 03/13
Dr Karen R. JonscherUniversity of Colorado Denver EB liaison: 04/11 - 03/12
Prof. Edouard NiceMonash University Member: 07/12 - 03/13
Angel SampsonUniversity of FloridaMember: 09/18 -
Alan SawyerThe Jackson LaboratoryMember:
Jack SimpsonUS Pharmacopeia EB Liaison: 04/12 - 03/13
Tracy TriplettVanderbilt UniversityMember:
Paula B. TurpenUniversity of Nebraska Medical Center EB Liaison: 03/13 - 04/14
Dr. Anthony T. YeungFox Chase Cancer Ctr EB Liaison: 04/10 - 03/11
Frances Weis-GarciaMemorial Sloan Kettering Cancer CenterEB Liaison: 04/14 - 02/16
Back to Top